📉 TORNTPHARM initially traded below the ₹4,814 VRZ Low, creating the conditions for a potential bullish BOF reversal. ⚠️ Price spent a large part of the session below the key level, showing that the initial recovery lacked strength. 🔎 Later, buyers pushed price back toward the VRZ Low, bringing the reversal setup into focus.
🔻 The stock maintained a weak structure during the first half of the session, with price moving toward the ₹4,760 area. 📊 A gradual recovery developed afterward, with buyers producing higher intraday levels. 🎯 However, the recovery needed sustained acceptance above ₹4,814 to validate the bullish BOF.
🔄 TORNTPHARM eventually reclaimed the ₹4,814 VRZ Low, creating a potential bullish reversal signal. 🟢 Buyers pushed price toward ₹4,830, but the move failed to hold above the key zone. 🚫 The subsequent sharp rejection brought price back toward ₹4,812.50, showing that the reclaim lacked sustained acceptance.
🟢 The later-session recovery showed improving bullish momentum, with consecutive green candles pushing price above ₹4,814. ⚡ However, the move toward ₹4,830 was followed by a strong bearish candle. 🔴 Price returned to the VRZ Low area, indicating that buyers could not maintain control after the breakout.
🎯 The bullish BOF required sustained acceptance above ₹4,814 after the reclaim. 🚫 Although price moved above the level, the breakout did not hold and was followed by a sharp rejection. ⚠️ Entering without waiting for confirmation could expose the trade to a failed reversal. 🧭 Reclaim + acceptance + bullish follow-through would provide stronger execution confirmation.
🔒 The failed hold above ₹4,814 highlights the importance of protecting against false reclaims. ⚠️ When price quickly loses a reclaimed VRZ level, the bullish thesis should be reassessed. 🛑 Respecting the invalidation condition can help limit exposure when the expected reversal loses momentum.
🧩 A successful reclaim can create confidence that the reversal is underway, but 👀 traders still need to observe whether price can actually sustain above the zone. ⚠️ The rejection near ₹4,830 demonstrated that the initial bullish momentum was not enough to maintain acceptance. 🎯 The key lesson is to confirm the quality of the reclaim, not simply react to the first move above the VRZ.
📊 TORNTPHARM demonstrates how a VRZ Low reclaim can still fail without sustained acceptance. 🔄 Buyers managed to push price above ₹4,814 and briefly toward ₹4,830, but 🔴 sellers quickly rejected the move. 🎯 The failure to hold above the VRZ Low became the key warning signal for the bullish BOF setup.
